2009
Molecular Analysis of Tumor-Promoting CD8+ T Cells in Two-Stage Cutaneous Chemical Carcinogenesis
Kwong BY, Roberts SJ, Silberzahn T, Filler RB, Neustadter JH, Galan A, Reddy S, Lin WM, Ellis PD, Langford CF, Hayday AC, Girardi M. Molecular Analysis of Tumor-Promoting CD8+ T Cells in Two-Stage Cutaneous Chemical Carcinogenesis. Journal Of Investigative Dermatology 2009, 130: 1726-1736. PMID: 19924136, PMCID: PMC2920801, DOI: 10.1038/jid.2009.362.Peer-Reviewed Original ResearchMeSH Keywords9,10-Dimethyl-1,2-benzanthraceneAmphiregulinAnimalsCD8-Positive T-LymphocytesCell DifferentiationDisease Models, AnimalEGF Family of ProteinsForkhead Transcription FactorsGene Expression ProfilingGlycoproteinsHepatitis A Virus Cellular Receptor 2Intercellular Signaling Peptides and ProteinsInterleukin-10Interleukin-17MiceMice, KnockoutReceptors, Antigen, T-Cell, alpha-betaReceptors, VirusSkin NeoplasmsConceptsTumor-infiltrating lymphocytesT cellsCutaneous carcinogenesisIL-17-producing T cellsT-proCutaneous chemical carcinogenesisTricolor flow cytometryContribution of inflammationCytolytic T cellsTumor-bearing miceEpithelial growth factorMechanism of actionT helperCancer immunotherapyUseful biomarkerMalignant progressionFlow cytometryClear associationGrowth factorReduced cytotoxicChemical carcinogenesisCarcinogenesisPro phenotypeWhole genome expression analysisTime-course analysis
2003
Selective immmunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow
Girardi M, Knobler R, Edelson R. Selective immmunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow. Hematology/Oncology Clinics Of North America 2003, 17: 1391-1403. PMID: 14710891, DOI: 10.1016/s0889-8588(03)00106-0.Peer-Reviewed Original ResearchConceptsLow side effect profileSide effect profilePotential novel strategyMechanism of actionImmunosuppressive medicationsExtracorporeal photochemotherapyEffect profileTransplant rejectionTreatment of cancerClinical recordsRole of ECPClinical studiesT cellsTreatment considerationsModern therapeuticsTreatmentNovel strategyGVHDMedicationsAutoimmunityCTCLMalignancyECPTherapyCancer